BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer
Phase 2
Completed
- Conditions
- Ovarian Neoplasms
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-11-17
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 246
- Registration Number
- NCT00791778
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
Completed
- Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Interventions
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2015-10-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1723
- Registration Number
- NCT00787657
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
Phase 2
Completed
- Conditions
- Venous ThrombosisDeep Vein Thrombosis
- Interventions
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 25
- Registration Number
- NCT00786422
Post Marketing Surveillance Study on Emselex After Launch in Germany
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2010-04-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 5821
- Registration Number
- NCT00786448
Sustainable Efficacy of Vardenafil OD Versus Vardenafil PRN in Erectile Dysfunction
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 236
- Registration Number
- NCT00786253
RDEA119 and Sorafenib Combination Dose Escalation Study
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 62
- Registration Number
- NCT00785226
- Locations
- 🇺🇸
UPenn, Philadelphia, Pennsylvania, United States
🇨🇦Toronto General Hospital, Toronto, Ontario, Canada
🇺🇸USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center, Los Angeles, California, United States
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A
Completed
- Conditions
- Hematologic DiseaseBlood Coagulation Disorders
- Interventions
- Behavioral: Recombinant Factor VIII (Kogenate, BAY 14-2222)
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 38
- Registration Number
- NCT00782470
Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.
Phase 4
Completed
- Conditions
- Energy Expenditure
- Interventions
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 22
- Registration Number
- NCT00781586
Comparative Efficacy of Bifonazole Cream vs Placebo After Nail Ablation With Urea Paste
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2013-06-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 693
- Registration Number
- NCT00781820
Rehabilitation Study in MS Patients
Phase 4
Terminated
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Drug: Interferon beta-1b, FRP within 15 days after randomizationDrug: Interferon beta-1b, FRP about 6 weeks after randomization
- First Posted Date
- 2008-10-27
- Last Posted Date
- 2015-05-29
- Lead Sponsor
- Bayer
- Target Recruit Count
- 4
- Registration Number
- NCT00780455